Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 49 min 37 sec ago

Aduro Announces License Agreement with Johnson and Johnson Innovation for Novel Immunotherapies for Prostate Cancer

Thu, 05/29/2014 - 14:17
BERKELEY, Calif.--(Healthcare Sales & Marketing Network)--Aduro BioTech, Inc., a clinical-stage biotechnology company, today announced that it has entered into an agreement granting Janssen Biotech, Inc. (Janssen) an exclusive, worldwide license to certain...
Biopharmaceuticals, Oncology, Licensing
Aduro BioTech, Janssen, Johnson & Johnson, immunotherapy, prostate cancer

CASMED and Century Medical Execute Distribution Agreement for FORE-SIGHT(R) Oximeters in Japan

Thu, 05/29/2014 - 14:12
Shipments Expected to Begin in the Third Quarter, Following Receipt of Regulatory Approval BRANFORD, Conn., May 29, 2014 -- (Healthcare Sales & Marketing Network) -- CAS Medical Systems, Inc. (CASM) (CASMED), a leader in medical devices for non-invasive...
Devices, Monitoring, Distribution
CAS Medical Systems, FORE-SIGHT ELITE, Cerebral Oximeter

Islet Sciences, Inc. Appoints Steven Delmar as Chief Financial Officer

Thu, 05/29/2014 - 14:09
RALEIGH, N.C., May 29, 2014 -- (Healthcare Sales & Marketing Network) -- Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical company developing novel technologies for the diagnosis and treatment of metabolic disease, announced today the appointment of...
Biopharmaceuticals, Endocrinology, Personnel
Islet Sciences, diabetes

Masimo Announces CE Mark of iSpO2(TM) Rx Pulse Oximeter for Mobile Devices

Thu, 05/29/2014 - 14:07
IRVINE, CA--(Healthcare Sales & Marketing Network) - Masimo (NASDAQ: MASI) today announced that the iSpO2 ™ Rx Pulse Oximeter for Android™ and iOS devices has received CE Mark clearance for medical use in select countries, offering clinicians the power of ...
Devices, Monitoring, Regulatory
Masimo, iSpO2 Rx, Pulse Oximeter

Mylan Launches Generic Malarone(R) Tablets

Thu, 05/29/2014 - 14:02
PITTSBURGH, May 29, 2014 -- (Healthcare Sales & Marketing Network) -- Mylan Inc. (MYL) today announced that it has launched Atovaquone and Proguanil Hydrochloride Tablets, 62.5 mg/25 mg and 250 mg/100 mg, the generic version of GlaxoSmithKline's Malarone&...
Biopharmaceuticals, Generics, Product Launch
Mylan, Proguanil, GlaxoSmithKline, Malarone

Hansen Medical Announces First Clinical Cases in United States With New Magellan(TM) 6Fr Robotic Catheter

Wed, 05/28/2014 - 14:38
MOUNTAIN VIEW, CA--(Healthcare Sales & Marketing Network) - Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in Intravascular Robotics, today announced the successful completion of the first clinical procedures in the United States using the Magellan™ ...
Devices, Interventional
Hansen Medical, Robotic Catheter

Allergan Confirms Receipt of Revised, Unsolicited Proposal from Valeant

Wed, 05/28/2014 - 14:35
Advises Stockholders to Take No Action at This Time IRVINE, Calif.--(Healthcare Sales & Marketing Network)--Allergan, Inc. (AGN) (“Allergan” or the “Company”) today confirmed that it has received a revised, unsolicited proposal from Valeant Pharmaceutic...
Biopharmaceuticals, Mergers & Acquisitions
Allergan, Valeant Pharmaceuticals

Retrophin Names Stephen Aselage President and Chief Operations Officer

Wed, 05/28/2014 - 14:28
Seasoned industry executive has strong track record in commercialization of rare disease products NEW YORK--(Healthcare Sales & Marketing Network)--Retrophin, Inc. (RTRX) today announced the appointment of Stephen Aselage as President and Chief Operatio...
Biopharmaceuticals, Personnel
Retrophin, Chenodal, Vecamyl

Mallinckrodt Pharmaceuticals’ New Drug Application Accepted for Review by FDA

Wed, 05/28/2014 - 14:24
Mallinckrodt’s MNK-155, a hydrocodone/acetaminophen extended-release combination, accepted for filing by U.S. Food and Drug Administration U.S. Patent Office notice of allowance covers the product’s composition and release profile DUBLIN--(Healthcar...
Biopharmaceuticals, FDA
Mallinckrodt, MNK-155, hydrocodone, acetaminophen

Varian Medical Systems To Equip New Proton Treatment Center at the National Taiwan University in Taipei

Tue, 05/27/2014 - 17:51
PALO ALTO, Calif., May 27, 2014 -- (Healthcare Sales & Marketing Network) -- Varian Medical Systems (VAR) today announced that it has signed an agreement with YongLin Healthcare Foundation by which Varian will provide its ProBeam® proton therapy syste...
Devices, Oncology
Varian Medical Systems, ProBeam, proton therapy, radiotherapy

Bristol-Myers Squibb and CytomX Therapeutics Announce Worldwide Collaboration to Develop Probody(TM) Therapeutics Against Multiple Immuno-Oncology Targets

Tue, 05/27/2014 - 13:07
NEW YORK & SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) and CytomX Therapeutics, Inc. today announced the companies have signed a worldwide research collaboration and license agreement to discover,...
Biopharmaceuticals, Oncology
Bristol-Myers Squibb, CytomX Therapeutics, Probody

Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies

Tue, 05/27/2014 - 13:00
Phase I/II study to evaluate nivolumab, Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor with Incyte’s investigational oral IDO1 inhibitor for multiple cancers NEW YORK & WILMINGTON, Del.--(Healthcare Sales & Marketing Network)--B...
Biopharmaceuticals, Oncology
Bristol-Myers Squibb, Incyte, nivolumab, INCB24360, immunotherapies

Spinifex Pharmaceuticals Strengthens Scientific Advisory Board (SAB) with Experts in Chronic Pain

Tue, 05/27/2014 - 12:53
Expanded SAB will oversee development of EMA401, Company's lead program for treating chronic pain MELBOURNE, Australia, May 27, 2014 -- (Healthcare Sales & Marketing Network) -- Spinifex Pharmaceuticals, a pain drug development company, today announces...
Biopharmaceuticals, Personnel
Spinifex Pharmaceuticals

Orient EuroPharma and Debiopharm Group(TM) Announce Their Partnership and the Launch of Pamorelin(R) LA in Singapore

Tue, 05/27/2014 - 12:46
SINGAPORE and LAUSANNE, Switzerland, May 27, 2014 -- (Healthcare Sales & Marketing Network) -- Orient EuroPharma Co., Ltd. (Orient EuroPharma) a specialty pharmaceutical company focused in marketing and commercialization with subsidiaries across Hong Kong...
Biopharmaceuticals, Oncology
Debiopharm, Orient EuroPharma, Pamorelin, prostate cancer

eNeura, Inc. Receives FDA Clearance for SpringTMS(R) Migraine Treatment Device

Fri, 05/23/2014 - 14:19
SpringTMS is the first medical device available to patients in the United States to relieve the pain caused by migraine headaches that are preceded by an aura eNeura to initiate post-market open-label study with leading headache specialists BALTIMORE...
Devices, Neurology, FDA
eNeura Inc, SpringTMS, migraine, single-pulse, Transcranial Magnetic Stimulation

Teva Received FDA Approval for QVAR(R) (beclomethasone dipropionate HFA) with Dose Counter

Fri, 05/23/2014 - 14:10
All Teva Respiratory Brands in the United States Will Soon Be Available With a Dose Counter JERUSALEM--(Healthcare Sales & Marketing Network)--Teva Pharmaceutical Industries Ltd., (TEVA) today announced that the U.S. Food and Drug Administration (FDA) h...
Biopharmaceuticals, FDA
Teva Pharmaceutical, QVAR , beclomethasone, asthma

RaySearch Laboratories: RaySearch receives 510(k) clearance for Pencil Beam Scanning with protons

Fri, 05/23/2014 - 13:11
STOCKHOLM--(Healthcare Sales & Marketing Network)--RaySearch Laboratories AB (STO:RAYB)in December 2013 an extended version of RaySearch’s RayStation® 4.0 treatment planning system was CE-marked and released for clinical use to multiple markets. The ne...
Devices, Oncology, FDA
RaySearch Laboratories, RayStation, proton therapy, radiotherapy

OrbusNeich Releases Long-term Data for World's First and Only Dual Therapy Stent

Fri, 05/23/2014 - 13:02
COMBO™ Dual Therapy Stent shown to actively promote rapid endothelialization and deliver long-term, true vessel healing HONG KONG, May 23, 2014 -- (Healthcare Sales & Marketing Network) -- OrbusNeich today announced long-term results from its REMEDEE T...
Devices, Interventional Cardiology
OrbusNeich, COMBO stent, Dual Therapy Stent, drug eluting stent

EkoSonic(R) Endovascular System Receives FDA Clearance for the Treatment of Pulmonary Embolism in the USA

Fri, 05/23/2014 - 12:51
BOTHELL, Wash.--(Healthcare Sales & Marketing Network)--23 May 2014: EKOS Corporation, a BTG International group company (BTG plc (BTG.L)), today announced that the U.S. Food and Drug Administration (FDA) has cleared the EkoSonic® Endovascular System f...
Devices, Interventional, FDA
EKOS Corp, EkoSonic, pulmonary embolism

iRhythm Secures $17 Million in Funding Led by Novo A/S as Company Sees Record Growth for Its ZIO(R) Service

Thu, 05/22/2014 - 22:26
SAN FRANCISCO, May 22, 2014 -- (Healthcare Sales & Marketing Network) -- iRhythm Technologies, Inc., a healthcare information services company, today announced that it closed a $17 million Series E financing led by Novo A/S, a global life science investme...
Devices, Cardiology, Monitoring, Venture Capital
iRhythm Technologies, ZIO Service, arrhythmia

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong